Adagio Medical Holdings, Inc (ADGM)

Adagio Medical Holdings, Inc. (ADGM) stock has experienced notable volatility over the past six months. The stock's 52-week range has fluctuated between $0.63 and $2.87. While the stock saw an all-time high of $12.38 USD on March 3, 2021, it reached an all-time low of $0.63 USD on April 6, 2025. Over the past year, ADGM's stock has shown a 90.10% increase, but over the last six months, it has seen a -40.00% change. As of April 7, 2026, the share price was $1.18, marking a 47.54% increase from $0.80 on April 8, 2025. Key events impacting the stock price include earnings reports showing net losses, financing activities involving private placements, regulatory and clinical milestones such as FDA Breakthrough Device designation and IDE Approval, and insider activity with the CEO purchasing shares.

As a developmental stage medical device company with low or zero reported revenue in recent periods, there is no explicit information available to indicate significant demand seasonality for Adagio Medical Holdings, Inc.'s products and services. The company's current focus on clinical trials and regulatory approvals suggests that its financial performance is more heavily influenced by research and development milestones and market entry rather than seasonal fluctuations in demand.

Adagio Medical Holdings, Inc. is a developmental stage medical device company focused on innovating ablation technologies for treating cardiac arrhythmias. The company operates within the Healthcare sector, specifically in the Medical Devices industry. Adagio Medical's core business revolves around developing cryoablation systems that utilize ultra-low temperature technologies to create effective and safer lesions in heart tissue. Its product portfolio includes the iCLAS, vCLAS, and Cryopulse catheters and accessories. The vCLAS™ System has received CE Mark approval and is currently undergoing evaluation in the FULCRUM-VT U.S. Pivotal IDE Trial.

Adagio Medical Holdings, Inc. is headquartered in Laguna Hills, California, USA. The company maintains a significant presence in the global medical device sector and is actively developing and placing its innovative ablation technologies on the European Union (EU) market. Its strategic focus for acquisitions and market expansion targets North American and European companies within the life sciences and medical technology sectors.

Adagio Medical Holdings, Inc. has experienced several positive developments impacting its brand reputation over the past year. The vCLAS Cryoablation System was granted Breakthrough Device designation by the U.S. FDA. A U.S. early feasibility study evaluating ultralow temperature cardiac ablation (ULTA) for scar-related ventricular tachycardia demonstrated a favorable safety profile. The company also completed cases with the vCLAS™ System under Expanded Access authorization from the U.S. FDA and completed enrollment in its -VT pivotal IDE trial. The company has also strengthened its leadership team with key appointments. Analyst consensus for ADGM stock is currently a "Strong Buy" with a 12-month price target of $4.0.

Adagio Medical Holdings, Inc. has a significant institutional ownership presence, with 23 institutional owners and shareholders collectively holding 16,645,650 shares. Major institutional shareholders include Perceptive Advisors Llc and RA Capital Management L.P. Insiders own 1.36% of the company, while institutions hold 11.43%.